We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+38.64%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.54B
AUM Growth
+$706M
Cap. Flow
+$104M
Cap. Flow %
4.08%
Top 10 Hldgs %
54.04%
Holding
74
New
12
Increased
16
Reduced
23
Closed
6

Top Buys

1
OLMA icon
Olema Pharmaceuticals
OLMA
+$312M
2
AMRN
Amarin Corp
AMRN
+$46.6M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$45.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$40.9M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$31.4M

Top Sells

1
SWTX
SpringWorks Therapeutics
SWTX
+$132M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$87.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$45.5M
4
REPL icon
Replimune Group
REPL
+$38.9M
5
XNCR icon
Xencor
XNCR
+$33.2M

Sector Composition

1 Healthcare 98.24%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHXM
51
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$6.12M 0.24%
62,500
– –
GLMD icon
52
Galmed Pharmaceuticals
GLMD
$4.43M
$5.6M 0.22%
9,998
– –
EUCRU
53
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$5.33M 0.21%
+500,000
New +$5.08M
FLACU
54
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$5.21M 0.2%
+500,000
New +$5.22M
CRIS icon
55
Curis
CRIS
$8.97M
$5.13M 0.2%
1,567
-7,558
-83% -$9.08M
XFOR icon
56
X4 Pharmaceuticals
XFOR
$356M
$5.1M 0.2%
26,430
– –
FVAM
57
DELISTED
5:01 Acquisition Corp
FVAM
$5.08M 0.2%
+500,000
New +$5.05M
PHAT icon
58
Phathom Pharmaceuticals
PHAT
$879M
$5.01M 0.2%
150,787
-171,311
-53% -$6.94M
RGLS
59
DELISTED
Regulus Therapeutics
RGLS
$4.56M 0.18%
337,621
+15,873
+5% +$117K
FWP
60
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.56M 0.18%
647,299
– –
VIRX
61
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.44M 0.14%
493,517
– –
JYAC
62
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$3.09M 0.12%
+300,000
New +$3.05M
RZLT icon
63
Rezolute
RZLT
$437M
$2.36M 0.09%
+190,814
New +$3.54M
SNCE
64
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.06M 0.04%
+5,000
New +$1.04M
FSTX
65
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$255K 0.01%
25,844
-209,449
-89% -$1.37M
VRDN icon
66
Viridian Therapeutics
VRDN
$1.99B
$160K 0.01%
+9,747
New +$147K
PANA.U
67
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$126K 0.01%
9,837
-790,163
-99% -$8.72M
SWTX
68
DELISTED
SpringWorks Therapeutics
SWTX
$4K ﹤0.01%
50
-2,053,941
-100% -$132M
ANAB icon
69
AnaptysBio
ANAB
$1.71B
– –
-1,227,405
Closed -$18.1M
BLRX
70
BioLineRX
BLRX
$13.1M
– –
-42,159
Closed -$2.77M
CLDX icon
71
Celldex Therapeutics
CLDX
$2.79B
– –
-3,066,797
Closed -$45.5M
EXEL icon
72
Exelixis
EXEL
$14B
– –
-15,300
Closed -$374K
REPL icon
73
Replimune Group
REPL
$847M
– –
-1,691,834
Closed -$38.9M
EVLO
74
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
– –
-65,000
Closed -$6.85M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
EAM
EULAV Asset Management Sarasota, Florida $3.12B AUM 13.38% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
AWM
Axxcess Wealth Management Carlsbad, California $3.12B AUM 21% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

BVF Inc's Q4 2020 Portfolio in Review

As of Q4 2020, BVF Inc held 74 positions worth $2.54B, up 38% from $1.84B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

BVF Inc deployed $104M of net new capital in Q4 2020, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Olema Pharmaceuticals: 6,661,503 shares worth $320M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $132M trimmed.

  • BVF Inc's largest Q4 2020 buy was Olema Pharmaceuticals: 6,661,503 shares worth $320M.
  • BVF Inc added most to Amarin Corp in Q4 2020, an estimated $46.6M increase.
  • BVF Inc's biggest Q4 2020 reduction was SpringWorks Therapeutics, cutting an estimated $132M.
  • BVF Inc fully exited Celldex Therapeutics in Q4 2020, selling an estimated $45.5M.
  • BVF Inc's ten largest holdings make up 54% of its $2.54B portfolio in Q4 2020.
  • BVF Inc opened 12 new positions and closed 6 in Q4 2020.
  • BVF Inc's portfolio value rose 38% quarter-over-quarter to $2.54B.

Based on BVF Inc's 13F filing for Q4 2020, filed 12 Feb 2021.